目的:了解骶骨脊索瘤的治疗概况。方法:查阅近年国内外关于骶骨脊索瘤的治疗方面相关文献,综述骶骨脊索瘤的手术治疗、放疗与化疗、分子生物学治疗方面新方法、新技术、新思路。结果:手术仍是骶骨脊索瘤治疗有效方法,术前靶血管栓塞技术等的使用可使术野更清晰、手术更便利;术前使白蛋白>3.0 g·L^-1、手术时间<6.0 h、手术由单一团队完成可降低术后切口并发症发生率;包括质子和碳离子的粒子束放疗及术中间隔放疗安全有效;骶骨脊索瘤的分子生物学特点为其治疗提供了新靶点及治疗途径。结论:肿瘤广泛切除术仍然安全有效且更加成熟;粒子束放疗及术中间隔放疗有望成为替代单纯手术治疗的新方法;骶骨脊索瘤的分子生物学特点为其治疗打开了新思路。

[1] KAYANI B,HANNA S A,SEWELL M D,et al.A review of the surgical management of sacral chordoma[J/OL].Eur J Surg Oncol,2014-04-25.pii:S0748-7983(14)00423-5.doi:10.1016/j.ejso.2014.04.008.
[2] 陈康武,杨惠林,陆俭,等.骶骨脊索瘤治疗的研究进展[J].脊柱外科杂志,2009,7(4):248-251.
[3] YONEMOTO T,TATEZAKI S,TAKENOUCHI T,et al.The surgical management of sacrococcygeal chordoma[J].Cancer,1999,85(4):878-883.
[4] SIMPSON A H,PORTER A,DAVIS A,et al.Cephalad sacral resection with a combined extended ilioinguinal and posterior approach[J].J Bone Joint Surg Am,1995,77(3):405-411.
[5] XU W P,SONG X W,YUE S Y,et al.Primary sacral tumors and their surgical treatment.A report of 87 cases[J].Chin Med J (Engl),1990,103(11):879-884.
[6] WUISMAN P,LIESHOUT O,SUGIHARA S,et al.Total sacrectomy and reconstruction:oncologic and functional outcome[J].Clin Orthop Relat Res,2000(381):192-203.
[7] 赵庆和,王田田,张俊丽,等.骶骨脊索瘤术前靶血管栓塞联合术中腹主动脉球囊阻断在临床中的应用[J].医学信息,2014(3):169.
[8] 袁峰,杨惠林,张志明,等.骶骨脊索瘤的靶血管栓塞和手术治疗[J].脊柱外科杂志,2003,1(2):89-91.
[9] 陈康武,杨惠林,陆俭,等.靶血管栓塞后手术治疗复发性骶骨脊索瘤的疗效分析[J].中国骨肿瘤骨病,2009,8(6):324-326.
[10] YANG H,ZHU L,EBRAHEIM N A,et al.Surgical treatment of sacral chordomas combined with transcatheter arterial embolization[J].J Spinal Disord Tech,2010,23(1):47-52.
[11] 乔智红,陈量,龙威.骶骨脊索瘤术前明胶海绵栓塞的应用[J].中国医师杂志,2012,2(z2):28-30.
[12] 郭卫,燕太强,汤小东,等.骶骨脊索瘤的手术治疗结果评价[J].中华外科杂志,2009,47(16):1224-1227.
[13] DUBORY A,MISSENARD G,LAMBERT B,et al."En bloc" resection of sacral chordomas by combined anterior and posterior surgical approach:a monocentric retrospective review about 29 cases[J].Eur Spine J,2014,23(9):1940-1948.
[14] SCHWAB J H,HEALEY J H,ROSE P,et al.The surgical management of sacral chordomas[J].Spine(Phila Pa 1976),2009,34(24):2700-2704.
[15] RUGGIERI P,ANGELINI A,USSIA G,et al.Surgical margins and local control in resection of sacral chordomas[J].Clin Orthop Relat Res,2010,468(11):2939-2947.
[16] ASAVAMONGKOLKUL A,WAIKAKUL S.Wide resection of sacral chordoma via a posterior approach[J].Int Orthop,2012,36(3):607-612.
[17] 曹东,肖建如,马俊明,等.骶骨脊索瘤的临床特点及综合治疗[J].脊柱外科杂志,2007,5(6):350-353.
[18] AHMED A R.Safety margins in resection of sacral chordoma:analysis of 18 patients[J].Arch Orthop Trauma Surg,2009,129(4):483-487.
[19] GUNTERBERG B.Effects of major resection of the sacrum.Clinical studies on urogenital and anorectal function and a biomechanical study on pelvic strength[J].Acta Orthop Scand Suppl,1976,162:1-38.
[20] CHEN K W,YANG H L,LU J,et al.Risk factors for postoperative wound infections of sacral chordoma after surgical excision[J].J Spinal Disord Tech,2011,24(4):230-234.
[21] WUISMAN P,LIESHOUT O,van DIJK M,et al.Reconstruction after total en bloc sacrectomy for osteosarcoma using a custom-made prosthesis:a technical note[J].Spine (Phila Pa 1976),2001,26(4):431-439.
[22] ZABEL-DU B A,NIKOGHOSYAN A,SCHWAHOFER A,et al.Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease[J].Radiother Oncol,2010,97(3):408-412.
[23] CHEN Y L,LIEBSCH N,KOBAYASHI W,et al.Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas[J].Spine (Phila Pa 1976),2013,38(15):E930-936.
[24] TAKAHASHI M,FUKUMOTO T,KUSUNOKI N,et al.Particle beam radiotherapy with a surgical spacer placement for unresectable sacral chordoma[J].Gan To Kagaku Ryoho,2010,37(12):2804-2806.
[25] MIMA M,DEMIZU Y,JIN D,et al.Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma[J].Br J Radiol,2014,87(1033):20130512.
[26] IMAI R L,KAMADA T,SUGAHARA S,et al.Carbon ion radiotherapy for sacral chordoma[J].Br J Radiol,2011,84(1):S48-54.
[27] NISHIDA Y,KAMADA T,IMAI R,et al.Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery[J].Int J Radiat Oncol Biol Phys,2011,79(1):110-116.
[28] IMAI R,KAMADA T,TSUJI H,et al.Effect of carbon ion radiotherapy for sacral chordoma:results of Phase Ⅰ-Ⅱ and Phase Ⅱ clinical trials[J].Int J Radiat Oncol Biol Phys,2010,77(5):1470-1476.
[29] HOF H L,WELZEL T,DEBUS J.Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma[J].Onkologie,2006,29(12):572-574.
[30] HUANG D L,CHEN Y,ZENG Q,et al.Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma[J].Korean J Radiol,2013,14(5):823-828.
[31] 阎庆辉,刘津,张国建,等.肿瘤相关凋亡诱导配体、Survivin、Caspase-3和NF-κB在大肠癌中的表达[J].中华实验外科杂志,2005,22(10):1197.
[32] WATANABE M,KITANO T,KONDO T,et al.Increase of nuclear ceramide through caspase-3-dependent regulation of the "sphingomyelin cycle" in Fas-induced apoptosis[J].Cancer Res,2004,64(3):1000-1007.
[33] 陈超,杨惠林,陈康武,等.生存素和半胱氨酰天冬氨酸特异性蛋白酶-3在骶骨脊索瘤中的表达及其与凋亡的相关性[J].中华实验外科杂志,2013,30(7):1416-1418.
[34] LI X 1,JI Z,MA Y,et al.Expression of hypoxia-inducible factor-1α,vascular endothelial growth factor and matrix metalloproteinase-2 insacral chordomas[J].Oncol Lett,2012,3(6):1268-1274.
[35] ZHOU M L,CHEN K,YANG H,et al.Expression of insulin-like growth factor Ⅱ mRNA-binding protein 3 (IMP3) in sacral chordoma[J].J Neurooncol,2014,116(1):77-82.
[36] LI X L,WANG S,CHEN Y,et al.Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence[J].Onkologie,2013,36(10):567-571.
[37] 王丹玲,蔡力力.VEGF、MMP-2及MMP-9在骨髓细胞中的表达及其与急性白血病的关系[J].现代医学,2008,36(1):30-33.
[38] CHEN K W L,YANG H L,LU J,et al.Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma[J].J Neurooncol,2011,101(3):357-363.